Format

Send to

Choose Destination
Therapie. 2016 Feb;71(1):97-105, 107-14. doi: 10.1016/j.therap.2016.01.005. Epub 2016 Feb 3.

"Big data" and "open data": What kind of access should researchers enjoy?

[Article in English, French]

Author information

1
Hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75908 Paris cedex 15, France. Electronic address: gilles.chatellier@aphp.fr.
2
LeLabEsanté, 75000 Paris, France.
3
AMGEN, 92650 Boulogne-Billancourt, France.
4
Beslay + Avocats, 75008 Paris, France.
5
Takeda France, 92977 Paris-La-Défense, France.
6
Hôpital La Timone, AP-HM, 13385 Marseille, France.
7
Inserm Transfert, 75013 Paris, France.
8
SNITEM, 92400 Courbevoie, France.
9
LEEM/ARIIS, 75858 Paris, France.
10
Abbott Vascular, 94518 Rungis, France.
11
DRCD, hôpital Saint-Louis, AP-HP, 75475 Paris, France.
12
Bristol-Myers-Squibb, 92500 Rueil-Malmaison, France.
13
DREES, 75350 Paris, France.
14
Sanofi France, 94255 Gentilly, France.
15
DMD Santé, 51100 Reims, France.
16
Direction centrale du service de santé des armées, 94160 Saint-Mandé, France.
17
Université de Bordeaux, 33076 Bordeaux, France.
18
SR Consulting, 75015 Paris, France.
19
CHU de Rennes, 35033 Rennes, France.

Abstract

The healthcare sector is currently facing a new paradigm, the explosion of "big data". Coupled with advances in computer technology, the field of "big data" appears promising, allowing us to better understand the natural history of diseases, to follow-up new technologies (devices, drugs) implementation and to participate in precision medicine, etc. Data sources are multiple (medical and administrative data, electronic medical records, data from rapidly developing technologies such as DNA sequencing, connected devices, etc.) and heterogeneous while their use requires complex methods for accurate analysis. Moreover, faced with this new paradigm, we must determine who could (or should) have access to which data, how to combine collective interest and protection of personal data and how to finance in the long-term both operating costs and databases interrogation. This article analyses the opportunities and challenges related to the use of open and/or "big data", from the viewpoint of pharmacologists and representatives of the pharmaceutical and medical device industry.

KEYWORDS:

Anonymization; Connected objects; Data storage; “Big data”; “Open data”

PMID:
27080635
DOI:
10.1016/j.therap.2016.01.005
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center